Efforts of the WHO/IUATLD to solve the problem of poor bioavailability of rifampicin from FDC anti-tuberculosis products: Is a change required in the direction of the approach in view of recent findings? [3]

International Journal of Tuberculosis and Lung Disease

Volumn 5, Issue 9, 2001, Pages 880-882

  Singh, S ^a  

^a SAS Nagar   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DECOMPOSITION; DRUG FORMULATION; DRUG INDUSTRY; ENTERIC COATED TABLET; HUMAN; LETTER; LUNG TUBERCULOSIS; MEDICAL SOCIETY; PRIORITY JOURNAL; STOMACH PH; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; DRUG COMBINATIONS; HUMANS; RIFAMPIN; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 0034847472     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (12)

1. Fixed dose combination tablets for the treatment of tuberculosis
2. Quality assurance of fixed-dose combinations of antituberculosis medications. Proceedings of an IUATLD/WHO workshop Panel discussions I-III
3. A validated reversed-phase (C18) HPLC method for simultaneous determination of rifampicin, isoniazid and pyrazinamide in USP dissolution medium and simulated gastric fluid
4. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions
5. Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions
6. Stability of rifampicin in dissolution medium in presence of isoniazid
7. Drug combinations and bioavailability of rifampicin
8. Effect of antacids on oral absorption of rifampicin
9. Comparative bioavailability study of rifampicin from rifampicin-isoniazid capsules using urinary excretion data
10. Human bioavailabilty studies